DNMT3A and myelodysplastic syndrome: Somatic mutations of DNMT3A result in aberrant DNA methylation, disrupting normal hematopoietic stem cell (HSC) differentiation and self-renewal (1, 2, 12), and are associated with adverse overall survival (OS) in AML and myelodysplastic syndrome (MDS) patients (1, 3, 13, 14).